share_log

開拓藥業-B：截至二零二三年十二月三十一日止月份之股份發行人的證券變動月報表

KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

香港交易所 ·  Jan 2 03:37
Summary by Moomoo AI
開拓藥業-B（09939）於2024年1月2日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本在該月份未發生變動，上月底結存及本月底結存均為700,000,000股，每股面值0.0001美元，法定/註冊股本總額為70,000美元。報告中亦確認，公司在該月份內發行的證券已獲董事會授權，並已履行所有上市前提條件及法律規定。開拓藥業-B為一家在開曼群島註冊成立的有限公司，由主席、執行董事及行政總裁童友之呈交該報表。
開拓藥業-B（09939）於2024年1月2日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本在該月份未發生變動，上月底結存及本月底結存均為700,000,000股，每股面值0.0001美元，法定/註冊股本總額為70,000美元。報告中亦確認，公司在該月份內發行的證券已獲董事會授權，並已履行所有上市前提條件及法律規定。開拓藥業-B為一家在開曼群島註冊成立的有限公司，由主席、執行董事及行政總裁童友之呈交該報表。
Breakthrough Pharmaceuticals - B (09939) filed with Hong Kong Trading and Settlement Limited on January 2, 2024 the Monthly Securities Change Report for the year ended December 31, 2023. The report shows that the company's regulated/registered share capital remained unchanged during the month, with 700,000,000 shares deposited at the end of last month and deposits at the end of this month, with a face value of $0.0001 per share and a total regulated/registered share capital of $70,000. The report also confirms that the securities issued by the Company during the month have been authorized by the Board of Directors and have complied with all listing prerequisites and legal requirements. Discovery Pharmaceuticals-B, a limited company incorporated in the Cayman Islands, is presented by the Chairman, Executive Director and Chief Executive Officer, Tofu Yui.
Breakthrough Pharmaceuticals - B (09939) filed with Hong Kong Trading and Settlement Limited on January 2, 2024 the Monthly Securities Change Report for the year ended December 31, 2023. The report shows that the company's regulated/registered share capital remained unchanged during the month, with 700,000,000 shares deposited at the end of last month and deposits at the end of this month, with a face value of $0.0001 per share and a total regulated/registered share capital of $70,000. The report also confirms that the securities issued by the Company during the month have been authorized by the Board of Directors and have complied with all listing prerequisites and legal requirements. Discovery Pharmaceuticals-B, a limited company incorporated in the Cayman Islands, is presented by the Chairman, Executive Director and Chief Executive Officer, Tofu Yui.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more